RxDoctor Payments Data

Michael Campbell, DO

Family Medicine · Fall River, MANPI 1376523621

Payments from drug & device makers

$3,557in general payments, 2019–2025

Across 203 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$925
  • Novo Nordisk$485
  • Pfizer$311
  • Lilly USA, LLC$235
  • Abbott$192
  • Sunovion Pharmaceuticals Inc.$161
  • plus $1K from 29 others

What the payments were for

  • Food & beverage$3,557100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,557 in reported general payments places this provider in the 90th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$266,250
Medicare patients
348
Services billed
5,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,017$191,505
OzempicSemaglutide92$105,092
JardianceEmpagliflozin180$93,853
FarxigaDapagliflozin Propanediol229$87,164
BiktarvyBictegrav/Emtricit/Tenofov Ala51$50,161
RybelsusSemaglutide34$48,678
XareltoRivaroxaban176$37,539
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$26,976
LinzessLinaclotide143$25,622
TrulicityDulaglutide37$25,075
RexultiBrexpiprazole59$21,737
EntrestoSacubitril/Valsartan52$18,501
JanuviaSitagliptin Phosphate20$14,194
TradjentaLinagliptin61$11,507
Aripiprazole93$10,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$311$191,5051,017 claims
Novo NordiskOzempic, Rybelsus$485$153,770126 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$132$111,563253 claims
AstraZenecaFarxiga, Brilinta$925$92,248248 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$23$48,07785 claims
Johnson & JohnsonXarelto$31$37,539176 claims
AbbVieLinzess$96$25,622143 claims
Lilly USA, LLCTrulicity$235$25,07537 claims
NovartisEntresto$61$18,50152 claims
MerckJanuvia$150$14,19420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Fall River

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →